Isotretinoin as chemoprophylaxis for cutaneous malignancies in
            <scp>Muir‐Torre</scp>
            syndrome: A novel concept

Joshi, Tejas P; Farr, Morgan A.; Lewis, Daniel

doi:10.1111/dth.15540

Cited by 4 publications

(4 citation statements)

References 8 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More, oral chemoprophylaxis with retinoids (isotretinoin) for cutaneous tumours prevention could be an option for these patients. Other options include subcutaneous Interferon 2alpha and topic applications of retinoids (21)(22)(23)(24). A more recent breakthrough in this area are vaccines for immunoprevention of DNA mismatch repair deficient cancers, which show promising results in initial phases (25).…”

Section: Discussionmentioning

confidence: 99%

Muir-Torre Syndrome: a Long Way to Diagnosis

Turcas¹,

Fetică²,

Nagy³

2023

JMRO

View full text Add to dashboard Cite

"Muir-Torre syndrome, a subtype of Lynch syndrome, is a rare genetic disorder. We present the case of a female patient with a long family and personal history who was diagnosed with numerous benign and malignant tumours of various histology, including some with sebaceous features, beginning at the age of 41. The majority were cutaneous tumours, treated with complete resection, but they frequently recurred. Visceral cancers included endocervical adenocarcinoma, vulvar squamous-cell carcinoma and urothelial carcinoma, treated surgically, followed by systemic oncological treatments and external beam radiotherapy. Following a 20-year evolution, extensive genetic blood testing revealed a pathogenic variant in the MSH2 gene, c.1861C>T (p.Arg621*), in heterozygous state. In light of this unusual clinical presentation and molecular profile, the patient was finally diagnosed with Muir-Torre syndrome. The prognosis was poor, with an inoperable recurrence of the urothelial carcinoma and extensive lymph node dissemination of a vulvar squamous cell carcinoma."

show abstract

Section: Discussionmentioning

confidence: 99%

Muir-Torre Syndrome: a Long Way to Diagnosis

Turcas¹,

Fetică²,

Nagy³

2023

JMRO

View full text Add to dashboard Cite

show abstract

“…Although the beneficial effect of isotretinoin for MTS patients is described previously, 3,4 it is not routinely offered to these patients. An overview of doses used in these cases has been provided by Joshi et al 5 We found that the isotretinoin improved cosmesis and made clinical follow-up easier. New lesions were detected earlier, and suspicious lesions stood out more.…”

mentioning

confidence: 87%

“…Isotretinoin was chosen for its greater sebostatic effect when compared to other oral retinoids. 5 With the reduction in both the severity and the number of skin lesions, it is suspected that even the development of skin malignancies may be reduced. 3 Our patient reported improved quality of life since the initiation of the isotretinoin treatment.…”

mentioning

confidence: 99%

Retinoid use in Muir–Torre syndrome: a forgotten miracle drug

Garmyn

2023

Int J Dermatology

View full text Add to dashboard Cite

“…Hence, it was deemed that, despite strong preclinical evidence, topical tazarotene is not an effective means of BCC chemoprevention in NBCCS patients. Retinoids have also been used to prevent malignancy in other skin cancer-predisposing genodermatoses, such as Muir-Torre syndrome and Bazex Syndrome [ 10 , 11 , 228 ]. Overall, chemoprevention with oral isotretinoin remains the primary off-label prophylactic for NBCCS and XP patients [ 10 ].…”

Section: Clinical Applications Of Retinoids For Keratinocyte Carcinom...mentioning

confidence: 99%

The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review

Ramchatesingh

Villarreal

Arcuri

et al. 2022

IJMS

View full text Add to dashboard Cite

Retinoids are natural and synthetic vitamin A derivatives that are effective for the prevention and the treatment of non-melanoma skin cancers (NMSC). NMSCs constitute a heterogenous group of non-melanocyte-derived skin cancers that impose substantial burdens on patients and healthcare systems. They include entities such as basal cell carcinoma and cutaneous squamous cell carcinoma (collectively called keratinocyte carcinomas), cutaneous lymphomas and Kaposi’s sarcoma among others. The retinoid signaling pathway plays influential roles in skin physiology and pathology. These compounds regulate diverse biological processes within the skin, including proliferation, differentiation, angiogenesis and immune regulation. Collectively, retinoids can suppress skin carcinogenesis. Both topical and systemic retinoids have been investigated in clinical trials as NMSC prophylactics and treatments. Desirable efficacy and tolerability in clinical trials have prompted health regulatory bodies to approve the use of retinoids for NMSC management. Acceptable off-label uses of these compounds as drugs for skin cancers are also described. This review is a comprehensive outline on the biochemistry of retinoids, their activities in the skin, their effects on cancer cells and their adoption in clinical practice.

show abstract

Isotretinoin as chemoprophylaxis for cutaneous malignancies in Muir‐Torre syndrome: A novel concept

Cited by 4 publications

References 8 publications

Muir-Torre Syndrome: a Long Way to Diagnosis

Muir-Torre Syndrome: a Long Way to Diagnosis

Retinoid use in Muir–Torre syndrome: a forgotten miracle drug

The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review

Contact Info

Product

Resources

About